Covid-19 Vaccines — Immunity, Variants, Boosters | NEJM

  • 1. Gasteiger G, D’Osualdo A, Schubert DA, Weber A, Bruscia EM, Hartl D. Cellular innate immunity: an old game with new players. J Innate Immun 2017;9:111125.

  • 2. Bartsch YC, Tong X, Kang J, et al. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci Transl Med 2022;14(642):eabn9243eabn9243.

  • 3. Chung AW, Kumar MP, Arnold KB, et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 2015;163:988998.

  • 4. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184:861880.

  • 5. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020;183(4):9961012.e19.

  • 6. Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 2021;374(6572):abm0829abm0829.

  • 7. Bange EM, Han NA, Wileyto P, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med 2021;27:12801289.

  • 8. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 2020;369:812817.

  • 9. Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 2020;586:583588.

  • 10. Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med 2020;383:15441555.

  • 11. van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 2020;586:578582.

  • 12. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 2020;369:806811.

  • 13. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022 June 23 (Epub ahead of print).

  • 14. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:26032615.

  • 15. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403416.

  • 16. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021;384:21872201.

  • 17. Hardt K, Vandebosch A, Sadoff J, et al. Efficacy and safety of a booster regimen of Ad26.COV2.S vaccine against Covid-19. January 31, 2022 (https://www.medrxiv.org/content/10.1101/2022.01.28.22270043v1). preprint.

  • 18. Gray G, Collie S, Goga A, et al. Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against omicron variant in South Africa. N Engl J Med 2022;386:22432245.

  • 19. See I, Lale A, Marquez P, et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination — United States, December 2020 to August 2021. Ann Intern Med 2022;175:513522.

  • 20. See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 2021;325:24482456.

  • 21. Bekker L-G, Garrett N, Goga A, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet 2022;399:11411153.

  • 22. Takuva S, Takalani A, Garrett N, et al. Thromboembolic events in the South African Ad26.COV2.S vaccine study. N Engl J Med 2021;385:570571.

  • 23. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:21242130.

  • 24. Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021;385:16801689.

  • 25. Sangli S, Virani A, Cheronis N, et al. Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine. Ann Intern Med 2021;174:14801482.

  • 26. Ling RR, Ramanathan K, Tan FL, et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir Med 2022;10:679688.

  • 27. Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 2022;327:331340.

  • 28. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med 2021;385:21402149.

  • 29. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 2021;385:21322139.

  • 30. Heymans S, Cooper LT. Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat Rev Cardiol 2022;19:7577.

  • 31. Verma AK, Lavine KJ, Lin C-Y. Myocarditis after Covid-19 mRNA vaccination. N Engl J Med 2021;385:13321334.

  • 32. Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 2021;326:13901399.

  • 33. Schauer J, Buddhe S, Gulhane A, et al. Persistent cardiac magnetic resonance imaging findings in a cohort of adolescents with post-coronavirus disease 2019 mRNA vaccine myopericarditis. J Pediatr 2022;245:233237.

  • 34. Falsey AR, Frenck RW Jr, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med 2021;385:16271629.

  • 35. Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 2021;384:8082.

  • 36. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med 2021;384:22592261.

  • 37. Pegu A, O’Connell SE, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science 2021;373:13721377.

  • 38. Collier AY, Yu J, McMahan K, et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. N Engl J Med 2021;385:20102012.

  • 39. Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature 2021;596:268272.

  • 40. Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA 2021;325:15351544.

  • 41. Polinski JM, Weckstein AR, Batech M, et al. Durability of the single-dose Ad26.COV2.S vaccine in the prevention of COVID-19 infections and hospitalizations in the US before and during the delta variant surge. JAMA Netw Open 2022;5(3):e222959e222959.

  • 42. Barouch DH, Stephenson KE, Sadoff J, et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N Engl J Med 2021;385:951953.

  • 43. Zhang Z, Mateus J, Coelho CH, et al. Humoral and cellular immune memory to four COVID-19 vaccines. March 21, 2022 (https://www.biorxiv.org/content/10.1101/2022.03.18.484953v1). preprint.

  • 44. Zheutlin A, Ott M, Sun R, et al. Durability of protection against COVID-19 breakthrough infections and severe disease by vaccines in the United States. January 6, 2022 (https://www.medrxiv.org/content/10.1101/2022.01.05.22268648v1). preprint.

  • 45. Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 vaccine effectiveness in New York State. N Engl J Med 2022;386:116127.

  • 46. Lin D-Y, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina. N Engl J Med 2022;386:933941.

  • 47. Gharpure R, Sami S, Vostok J, et al. Multistate outbreak of SARS-CoV-2 infections, including vaccine breakthrough infections, associated with large public gatherings, United States. Emerg Infect Dis 2022;28:3543.

  • 48. Collier AY, Brown CM, McMahan KA, et al. Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Sci Transl Med 2022;14(641):eabn6150eabn6150.

  • 49. Siddle KJ, Krasilnikova LA, Moreno GK, et al. Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. Cell 2022;185(3):485492.e10.

  • 50. Turner JS, O’Halloran JA, Kalaidina E, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 2021;596:109113.

  • 51. Kim W, Zhou JQ, Horvath SC, et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 2022;604:141145.

  • 52. Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022;386:10461057.

  • 53. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021;371(6529):eabf4063eabf4063.

  • 54. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590:630634.

  • 55. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020;181(7):14891501.e15.

  • 56. Collier AY, Yu J, McMahan K, et al. Coronavirus disease 2019 messenger RNA vaccine immunogenicity in immunosuppressed individuals. J Infect Dis 2022;225:11241128.

  • 57. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:22042206.

  • 58. Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 2020;182(4):812827.e19.

  • 59. Hou YJ, Chiba S, Halfmann P, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 2020;370:14641468.

  • 60. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2022;602:654656.

  • 61. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nature 2022;604:553556.

  • 62. Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 2022;602:676681.

  • 63. Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 variants. N Engl J Med 2022;386:15791580.

  • 64. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa. Nature 2022;603:679686.

  • 65. Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022;387:8688.

  • 66. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection. Nature 2022 June 17 (Epub ahead of print).

  • 67. Khan K, Karim F, Ganga Y, et al. Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity. May 1, 2022 (https://www.medrxiv.org/content/10.1101/2022.04.29.22274477v1). preprint.

  • 68. Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 omicron. Nature 2022;602:682688.

  • 69. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med 2022;386:492494.

  • 70. Pajon R, Doria-Rose NA, Shen X, et al. SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med 2022;386:10881091.

  • 71. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION Network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:255263.

  • 72. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against omicron in Israel. N Engl J Med 2022;386:17121720.

  • 73. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection and vaccination on symptomatic omicron infections. N Engl J Med 2022;387:2134.

  • 74. Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med 2022;386:22012212.

  • 75. Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron. Nature 2022;603:493496.

  • 76. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize omicron. Nature 2022;603:488492.

  • 77. Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron. Cell 2022;185(5):847859.e11.

  • 78. Tostanoski LH, Chandrashekar A, Patel S, et al. Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. NPJ Vaccines 2022;7:22.

  • 79. Corbett KS, Nason MC, Flach B, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 2021;373(6561):eabj0299eabj0299.

  • 80. Chandrashekar A, Yu J, McMahan K, et al. Vaccine protection against the SARS-CoV-2 omicron variant in macaques. Cell 2022;185(9):15491555.e11.

  • 81. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022;375:4350.

  • 82. Fong Y, McDermott AB, Benkeser D, et al. Immune correlates analysis of a single Ad26.COV2.S dose in the ENSEMBLE COVID-19 vaccine efficacy clinical trial. April 12, 2022 (https://www.medrxiv.org/content/10.1101/2022.04.06.22272763v1). preprint.

  • 83. Gagne M, Moliva JI, Foulds KE, et al. mRNA-1273 or mRNA-omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from omicron. Cell 2022;185(9):15561571.e18.

  • 84. Tan CS, Collier AY, Yu J, et al. Durability of heterologous and homologous COVID-19 vaccine boosts. JAMA Netw Open 2022;5(8):e2226335e2226335.

  • 85. Liu X, Munro APS, Feng S, et al. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial. J Infect 2022;84:795813.

  • We would love to thank the author of this write-up for this incredible content

    Covid-19 Vaccines — Immunity, Variants, Boosters | NEJM

    You can view our social media profiles here as well as other pages related to them here.https://paw6.info/related-pages/